地拉罗司应如何使用呢？

Deferasirox is a tridentate iron chelator that combines with ferric iron ions in a 2:1 ratio to form a complex that is excreted in the feces, thereby reducing iron storage in the body. Because Deferasirox continues to exist in plasma, it can continuously reduce plasma non-transferrin-bound iron and directly remove iron formed from toxicity in the body. So, how should Deferasirox be used?

Starting dose: 1. The recommended starting dose of Deferasirox is 20 mg/kg.

2. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month for adults) and need to reduce excessive iron exposure, a starting dose of 30 mg/kg/day may be considered.

3. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month for adults) and who need to maintain iron balance in the body, a starting dose of 10 mg/kg/day may be considered.

4. For patients who have already responded well to deferoxamine treatment, the initial dose of Enriga may be equivalent to half of the dose of deferoxamine. (For example, a patient receiving deferoxamine 40 mg/kg/day, 5 days a week or equivalent, may start with 20 mg/kg if switched to Enriga.)

How to take:

Deferasirox should be taken once daily on an empty stomach, at least 30 minutes before a meal, preferably at the same time each day. Tablets should not be chewed or swallowed whole.

Deferasirox (Deferasirox) should not be taken together with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet.

Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before taking. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

Deferasirox was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for Deferasirox (Deferasirox) for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

The above is the content of how to take Deferasirox. I hope it can help you!